000			01762 a2200505 4500
005			20250513231129.0
264		0	_c20010614
008			200106s 0 0 eng d
022			_a1524-4539
024	7		_a10.1161/01.cir.103.7.961 _2doi
040			_aNLM _beng _cNLM
100	1		_aChew, D P
245	0	0	_aDefining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. _h[electronic resource]
260			_bCirculation _cFeb 2001
300			_a961-6 p. _bdigital
500			_aPublication Type: Journal Article; Meta-Analysis
650	0	4	_aAbciximab
650	0	4	_aAngioplasty, Balloon, Coronary _xadverse effects
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aCoronary Disease _xcomplications
650	0	4	_aDemography
650	0	4	_aDiabetes Complications
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Therapy, Combination
650	0	4	_aHemorrhage _xetiology
650	0	4	_aHeparin _xadverse effects
650	0	4	_aHumans
650	0	4	_aImmunoglobulin Fab Fragments _xtherapeutic use
650	0	4	_aIncidence
650	0	4	_aMiddle Aged
650	0	4	_aRandomized Controlled Trials as Topic _xstatistics & numerical data
650	0	4	_aRisk Assessment
650	0	4	_aRisk Factors
650	0	4	_aThrombosis _xetiology
650	0	4	_aTreatment Outcome
650	0	4	_aWhole Blood Coagulation Time
700	1		_aBhatt, D L
700	1		_aLincoff, A M
700	1		_aMoliterno, D J
700	1		_aBrener, S J
700	1		_aWolski, K E
700	1		_aTopol, E J
773	0		_tCirculation _gvol. 103 _gno. 7 _gp. 961-6
856	4	0	_uhttps://doi.org/10.1161/01.cir.103.7.961 _zAvailable from publisher's website
999			_c11119726 _d11119726